ARTICLE | Company News
Memory reacquires PDE-4 compounds
August 20, 2005 12:20 AM UTC
MEMY reacquired rights to phosphodiesterase-4 (PDE-4) inhibitors MEM 1414 and MEM 1917 from Roche (SWX:ROCZ). Under a 2002 deal, ROCZ maintains its exclusive, worldwide license to develop and commercialize all other PDE-4 inhibitor candidates in MEMY's program. ...